SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix's upcoming earnings are sparking active debate, especially after the stock traded down in the after-hours session. While revenue was in line with estimates, EPS missed, and some community members are attributing the dip to a tax dispute in Brazil and broader concerns about content. A potential stock split and the impact of increased competition and advertising revenue are also key talking points.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending due to a proposed private offering of convertible senior notes, leading to community discussion about dilution and its impact on long-term holders; some view this as a strategic move to secure funding before positive catalysts, while others express concern about the company's financial management and potential for further offerings; the community is also debating the recent analyst downgrade and its effect on the stock's trajectory.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending due to its acquisition of Railbird, a prediction market platform, sparking discussions about the company's expansion into new markets beyond sports betting. While some express excitement about this growth and potential, others are skeptical, citing concerns about profitability and regulatory challenges, with community members closely watching how this move impacts the stock's value.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

ISRG is trending due to strong earnings and raised guidance, sparking debate about its valuation and future growth potential. While some community members celebrate the positive report and anticipate further gains, others express concerns about margin pressures and potential saturation in the US market. Bullish sentiment highlights the company's leadership in robotic surgery and potential for international expansion.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments is trending due to an earnings report that beat expectations but was followed by a weaker-than-expected forecast, sparking concerns about cautious commentary and potential impacts from trade tensions. The community is actively discussing whether the stock is overvalued and anticipating a significant price movement, with some expecting a bounce while others foresee further declines. Some traders believe analysts are paid to pump before ER as a tactic for unloading stock.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amidst speculation of a potential acquisition, with Paramount Skydance reportedly interested in making a bid, although the deal's likelihood is debated. Community chatter revolves around potential offer prices and whether WBD will accept, with some anticipating a bidding war involving other major players like Netflix or Comcast. The stock's movement reflects investor uncertainty surrounding these ongoing acquisition rumors and what price a deal could actually happen at.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Minerva Neurosciences Inc

Minerva Neurosciences ($NERV) is trending due to a massive surge following news of a $200M financing deal aimed at advancing its schizophrenia treatment. Community chatter revolves around the potential for significant gains, while some traders caution about a possible pump and dump, leading to high volatility. The funding is viewed as a strong indicator of confidence in the drug's approval, sparking debates about its long-term potential versus short-term trading opportunities.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

TERN is trending as investors analyze recent analyst ratings, upcoming catalysts related to their CML and obesity programs, and a strong cash position lasting into 2028. Unusual options activity and insider buying have also caught the attention of traders, though some express concern over lack of recent news and data. Community members are actively discussing potential buyout scenarios and comparing TERN's prospects to others in the GLP-1 space.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending as the stock experiences a significant pullback, prompting community discussion about potential bottom levels and future catalysts. Despite the recent downturn, some investors express confidence in the company's long-term prospects, citing a major deal with Microsoft and overall growth in the AI sector. Community members are actively debating whether to buy the dip or wait for further price declines.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs experienced a volatile trading period, initially surging on rare earth mining prospects and fixed-price automotive contracts. However, the stock quickly reversed course following an analyst downgrade and skepticism regarding the viability of the rare earth initiative. Community discussions center on potential acquisitions, the impact of analyst ratings, and overall market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions PR Newswire VANCOUVER, Oct. 21, 2025 Equity...

Fractyl Health (GUTS) announced on Friday that patients who stopped taking the GLP-1 class drug Tirzepatide and were treated with its Revita lost an additional 2.5% of their total body weight at three months in a trial. At the time of writing, shares of the company traded 28% higher on Friday afternoon.The study was designed to evaluate the Revita procedure in adults with obesity who achieved at least 15% total body weight loss with Tirzepatide, the active ingredient in Eli Lilly’s blockbuster weight loss drug Zepbound. Those who received a sham procedure after discontinuing Zepbound regained 10% total body weight in the study at three months, the company said.Revita is Fractyl’s lead product candidate. The procedure is designed to reverse damage to intestinal nutrient-sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets by remodeling the inner wall of the first part of the small intestine.“These results are clinically and statistically significant and provide randomized, blinded evidence that drug-free, durable weight maintenance is possible,” the company said, while adding that the study also supports Revita in post-GLP-1 weight maintenance.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/26/3156942/0/en/Fractyl-Health-Announces-Groundbreaking-Data-from-REMAIN-1-Midpoint-Cohort-Showing-Revita-Maintained-Weight-Loss-After-GLP-1-Discontinuation.html">stated</a> that no serious adverse events related to Revita were identified in the study, and side effects were infrequent and mild. The firm expects to file with the U.S. Food and Drug Administration for the approval of Revita in the second half of 2026.On Friday, the company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/26/3156951/0/en/Fractyl-Health-Announces-Pricing-of-60-Million-Underwritten-Offering-of-Common-Stock.html">announced</a> the pricing of an underwritten offering of 60 million shares of its common stock at $1.00 per share, representing a discount of about 1% from the stock’s closing price on Thursday. The gross proceeds from the offering are expected to be about $60 million, the company added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GUTS">GUTS stock</a> rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:622/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_26_at_1_00_54_PM_png_90a4342a59.webp" alt="GUTS' Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 26, 2025 | Source: Stocktwits" width="622" height="66"><figcaption>GUTS' Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 26, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed disappointment at the offering.<stembedurl>https://stocktwits.com/Stmkr/message/630122910</stembedurl>GUTS stock is down 38% this year and by about 49% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uber-reportedly-expects-non-restaurant-deliveries-to-surge-faster-than-previously-expected/chDVlUmR3eW">Uber Reportedly Expects Non-Restaurant Deliveries To Surge Faster Than Previously Expected</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

GUTS Stock Rallied About 28% Today – Here’s Why

Fractyl Health expects to file with the U.S. Food and Drug Administration for the approval of Revita in the second half of 2026.

Equity

Fractyl Health expects to file with the U.S. Food and Drug Administration for the approval of Revita in the second half of 2026.


Fractyl Health shares fell 27% in after-hours trading Tuesday after the company announced a public offering of common stock and pre-funded warrants.&nbsp;The offering includes accompanying common warrants, and Ladenburg Thalmann is acting as&nbsp;the sole book-running manager.Despite the market’s negative reaction to the capital raise, retail sentiment on Stocktwits remained optimistic, buoyed&nbsp;by the release of strong new clinical data hours earlier.&nbsp;The company shared two-year follow-up results from the Germany Real-World Registry study, which evaluated the Revita procedure in people with obesity and advanced type 2 diabetes (T2D) who had inadequately controlled glucose levels despite being on up to three glucose-lowering agents (GLAs).According to the study, a single Revita procedure led to a median weight loss of 9.6%, sustained over two years, with weight decreasing from 104 kg to 97 kg at year one and remaining stable through year two.&nbsp;Notably, 7 of 8 participants achieved at least a 5% weight reduction, and 5 of 8 saw reductions of 10% or more. Only one participant, who had a history of cortisone therapy known to cause weight gain, experienced&nbsp;a modest weight increase.Meanwhile, median HbA1c decreased from 9.6% to 7.2%, which was maintained over two years of follow-up. Patients were also able to reduce or stabilize the dosing of GLAs, and there were no device or procedure-related serious adverse events.Fractyl said the findings support the potential of Revita as a long-lasting, non-drug metabolic therapy and build momentum for its ongoing U.S. pivotal trial, REMAIN-1, which is under an IDE and is designed to assess Revita for weight maintenance after GLP-1 treatment.&nbsp;The company expects Midpoint Cohort data in the third quarter and primary endpoint data from the Pivotal Cohort in the second half of&nbsp; 2026.As of now, 34 patients are enrolled in the Germany registry, which is no longer recruiting but will continue with protocol-defined follow-up. Weight loss and glycemic benefits were observed as early as one month post-procedure and persisted throughout the study duration.Fractyl intends to use net proceeds from the offering, along with existing cash, to support both the Revita and Rejuva pipeline programs, and for working capital and general corporate purposes.On Stocktwits,&nbsp;<a href="https://stocktwits.com/symbol/GUTS">retail sentiment for Fractyl</a> was ‘extremely bullish’ amid a 124% surge in 24-hour message volume.One user said the strong two-year Revita data was a “big win” and that similar setups, including positive clinical news followed by a quick offering, have historically seen shares recover to pre-offering levels.&nbsp;While the user noted the company “could have done the PR’ing/offering a bit better,” they added the underlying science was “phenomenal” and called Revita a “first-in-class” product with major potential.<stembedurl>https://stocktwits.com/BioRich/message/623885253</stembedurl>Another user said they were buying into Fractyl, looking for either a short squeeze or a potential buyout.<stembedurl>https://stocktwits.com/garygb/message/623881828</stembedurl>Fractyl’s stock has declined 12.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Fractyl Health (GUTS) shares fell 27% in after-hours trading Tuesday after the company announced a public offering of common stock and pre-funded warrants. (Photo credit: Getty Images)

Fractyl Health Sinks After-Hours On Stock Offering, But Investors Cheer Durable Weight Loss Data

Retail optimism surged following new real-world data showing that patients with advanced type 2 diabetes sustained weight loss and glycemic improvements two years after a single Revita procedure.

Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company ), a metabolic therapeutics company focused on pioneering new approaches for the treatment of...

Fractyl Health reports Q4 EPS ($11.18) vs ($7.39) last year

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Received IDE approval for the Revita Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 Based Drugs Completion of enrollment in pivotal...

Fractyl Health Gains FDA Nod to Investigate Revita Device

Fractyl Health, Inc. (GUTS) just unveiled an update.

Fractyl Health, Inc. has announced a significant milestone with the FDA granting it Investigational Device Exemption to explore the effectiveness...

Fractyl Health Receives FDA IDE Approval for the Revita  Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs

Revita aims to be the first approved therapeutic option for durable weight maintenance after discontinuation of GLP-1 based drugs, as an adjunct to diet and exercise With this FDA IDE approval...

Fractyl Health receives FDA IDE approval for Revita Remain-1 pivotal study

Fractyl Health (NASDAQ:GUTS) Stock Price Down 6.2%

Fractyl Health, Inc. (NASDAQ:GUTS  Get Free Report)s stock price was down 6.2% during trading on Wednesday . The company traded as low as $7.10 and last traded at $7.20. Approximately...

Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.

Fractyl Health Inc.

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

GUTS
Fractyl Health Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GUTS News

GUTSFractyl Health Inc.